By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Novo Nordisk's shares tumbled as much as 20% ...

The stock tumbled 19% at the opening bell in Copenhagen after its outlook for the year ahead disappointed investors.

COPENHAGEN, Feb 4 () - Novo Nordisk CEO Mike ​Doustdar said on ‌Wednesday that the price reductions ‌for its obesity drug ...

By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising ...

This could finally be the start of the drugmaker's comeback.

Jan 30 (Reuters) - Novo Nordisk's Wegovy pill hit over 26,000 U.S. prescriptions in the second full week after its launch, ...

Anything that helps Americans lose weight, reduces treatment barriers and makes care more affordable should be welcomed. But ...

Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, has warned that profits and sales could fall by as much as 13 ...

Novo Nordisk said on Monday its experimental next-generation weight-loss drug CagriSema showed greater reductions in blood ...

Skye Bioscience reports Phase 2a data showing nimacimab plus semaglutide led to over 22% weight loss at 52 weeks, with lower ...

Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.

While CagriSema bested Novo Nordisk's Wegovy on blood sugar control in a late-stage trial, the next-gen weight loss drug still has not met the pharma's 25% weight loss goal.